Multi-peptide coupled-cell tolerance ameliorates ongoing relapsing EAE associated with multiple pathogenic autoreactivities

Journal of Autoimmunity

Volumn 27, Issue 4, 2006, Pages 218-231

  Smith, Cassandra E ^a   Miller, Stephen D ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Anergy; Antigens; Autoimmunity; EAE MS; Epitopes; Peptides; Suppression; T Cells; Tolerance

Indexed keywords

CANCER GROWTH FACTOR; CYANAMIDE; CYTOKINE; ENCEPHALITOGENIC PROTEIN; EPITOPE; ETHYLENE CARBODIIMIDE; INTERLEUKIN 10; MYELIN; MYELIN BASIC PROTEIN[84-104]; MYELIN OLIGODENDROCYTE PROTEIN[92-106]; PEPTIDE; PROTEOLIPID PROTEIN; PROTEOLIPID PROTEIN[139-151]; PROTEOLIPID PROTEIN[178-191]; UNCLASSIFIED DRUG;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOIMMUNITY; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; DELAYED HYPERSENSITIVITY; DRUG INHIBITION; DRUG TARGETING; FEMALE; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATORY CELL; MOUSE; MULTIPLE SCLEROSIS; NONHUMAN; PERIPHERAL NERVOUS SYSTEM; PRIORITY JOURNAL; RECURRENT DISEASE; SWISS JAMES LAMBERT MOUSE; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TH1 CELL;

AMINO ACID SEQUENCE; ANIMALS; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; EPITOPES; FEMALE; IMMUNE TOLERANCE; IMMUNIZATION; MICE; MOLECULAR SEQUENCE DATA; MULTIPLE SCLEROSIS; MYELIN SHEATH; PEPTIDE FRAGMENTS; T-LYMPHOCYTES;

EID: 33846681640     PISSN: 08968411     EISSN: 10959157     Source Type: Journal    
DOI: 10.1016/j.jaut.2006.12.002     Document Type: Article

References (74)

1. Hauser S.L., and Goodin D.S. Multiple sclerosis and other demyelinating diseases. In: Kasper D.L., Braunwald E., Fauci A.S., Hauser S.L., Longo D.L., Jameson J., and LIsselbacher K.J. (Eds). Harrison's principles of internal medicine. 16th ed. (2004), McGraw-Hill, New York
2. Haines J.L., Ter-Minassian M., Bazyk A., Gusella J.F., Kim D.J., Terwedow H., et al. A complete genomic screen for multiple sclerosis underscores a role for the major histocompatability complex. The Multiple Sclerosis Genetics Group. Nat Genet 13 (1996) 469-471
3. Sadovnick A.D., and Ebers G.C. Genetics of multiple sclerosis. Neurol Clin 13 (1995) 99-118
4. Barcellos L.F., Oksenberg J.R., Green A.J., Bucher P., Rimmler J.B., Schmidt S., et al. Genetic basis for clinical expression in multiple sclerosis. Brain 125 (2002) 150-158
5. Kurtzke J.F. Multiple sclerosis in time and space-geographic clues to cause. J Neurovirol 6 Suppl. 2 (2000) S134-S140
6. Zhang J., Markovic-Plese S., Lacet B., Raus J., Weiner H.L., and Hafler D.A. Increased frequency of interleukin 2-responsive T cells specific for myelin basic protein and proteolipid protein in peripheral blood and cerebrospinal fluid of patients with multiple sclerosis. J Exp Med 179 (1994) 973-984
7. Voskuhl R.R., Martin R., Bergman C., Dalal M., Ruddle N.H., and McFarland H.F. T helper 1 (Th1) functional phenotype of human myelin-basic protein-specific T lymphocytes. Autoimmunity 15 (1993) 137-143
8. Olsson T., Zhi W.W., Hîjeberg B., Kostulas V., Jiang Y.P., Anderson G., et al. Autoreactive T lymphocytes in multiple sclerosis determined by antigen-induced secretion of interferon-gamma. J Clin Invest 86 (1990) 981-985
9. Bielekova B., Muraro P.A., Golestaneh L., Pascal J., McFarland H.F., and Martin R. Preferential expansion of autoreactive T lymphocytes from the memory T-cell pool by IL-7. J Neuroimmunol 100 (1999) 115-123
10. Pettinelli C.B., and McFarlin D.E. Adoptive transfer of experimental allergic encephalomyelitis in SJL/J mice after in vitro activation of lymph node cells by myelin basic protein: requirement for Lyt 1 + 2- T lymphocytes. J Immunol 127 (1981) 1420-1423
11. Brostoff S.W., and Mason D.W. Experimental allergic encephalomyelitis: successful treatment in vivo with a monoclonal antibody that recognizes T helper cells. J Immunol 133 (1984) 1938-1942
12. Tuohy V.K., Lu Z., Sobel R.A., Laursen R.A., and Lees M.B. Identification of an encephalitogenic determinant of myelin proteolipid protein for SJL mice. J Immunol 142 (1989) 1523-1527
13. Goverman J., Woods A., Larson L., Weiner L.P., Hood L., and Zaller D.M. Transgenic mice that express a myelin basic protein-specific T cell receptor develop spontaneous autoimmunity. Cell 72 (1993) 551-560
14. Madsen L.S., Andersson E.C., Jansson L., Krogsgaard M., Andersen C.B., Engberg J., et al. A humanized model for multiple sclerosis using HLA-DR2 and a human T-cell receptor. Nat Genet 23 (1999) 343-347
15. McRae B.L., Vanderlugt C.L., Dal Canto M.C., and Miller S.D. Functional evidence for epitope spreading in the relapsing pathology of experimental autoimmune encephalomyelitis. J Exp Med 182 (1995) 75-85
16. McMahon E.J., Bailey S.L., Castenada C.V., Waldner H., and Miller S.D. Epitope spreading initiates in the CNS in two mouse models of multiple sclerosis. Nat Med 11 (2005) 335-339
17. Vanderlugt C.L., Eagar T.N., Neville K.L., Nikcevich K.M., Bluestone J.A., and Miller S.D. Pathologic role and temporal appearance of newly emerging autoepitopes in relapsing experimental autoimmune encephalomyelitis. J Immunol 164 (2000) 670-678
18. Yu M., Johnson J.M., and Tuohy V.K. A predictable sequential determinant spreading cascade invariably accompanies progression of experimental autoimmune encephalomyelitis: a basis for peptide-specific therapy after onset of clinical disease. J Exp Med 183 (1996) 1777-1788
19. Ellmerich S., Takacs K., Mycko M., Waldner H., Wahid F., Boyton R.J., et al. Disease-related epitope spread in a humanized T cell receptor transgenic model of multiple sclerosis. Eur J Immunol 34 (2004) 1839-1848
20. Klehmet J., Shive C., Guardia-Wolff R., Petersen I., Spack E.G., Boehm B.O., et al. T cell epitope spreading to myelin oligodendrocyte glycoprotein in HLA-DR4 transgenic mice during experimental autoimmune encephalomyelitis. Clin Immunol 111 (2004) 53-60
21. Tuohy V.K., Yu M., Weinstock-Guttman B., and Kinkel R.P. Diversity and plasticity of self recognition during the development of multiple sclerosis. J Clin Invest 99 (1997) 1682-1690
22. Tuohy V.K., Yu M., Yin L., Kawczak J.A., and Kinkel R.P. Spontaneous regression of primary autoreactivity during chronic progression of experimental autoimmune encephalomyelitis and multiple sclerosis. J Exp Med 189 (1999) 1033-1042
23. Tuohy V.K., Yu M., Yin L., Kawczak J.A., and Kinkel P.R. Regression and spreading of self-recognition during the development of autoimmune demyelinating disease. J Autoimmun 13 (1999) 11-20
24. Goebels N., Hofstetter H., Schmidt S., Brunner C., Wekerle H., and Hohlfeld R. Repertoire dynamics of autoreactive T cells in multiple sclerosis patients and healthy subjects: epitope spreading versus clonal persistence. Brain 123 (2000) 508-518
25. Muraro P.A., Wandinger K.P., Bielekova B., Gran B., Marques A., Utz U., et al. Molecular tracking of antigen-specific T cell clones in neurological immune-mediated disorders. Brain 126 (2003) 20-31
26. Hohol M.J., Olek M.J., Orav E.J., Stazzone L., Hafler D.A., Khoury S.J., et al. Treatment of progressive multiple sclerosis with pulse cyclophosphamide/methylprednisolone: response to therapy is linked to the duration of progressive disease. Mult Scler 5 (1999) 403-409
27. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group. Neurology 43 (1993) 655-661
28. Ebers G.C., Hommes O., Hughes R.A.C., Kappos L., Sandberg-Wollheim L., Palace J., et al. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Lancet 352 (1998) 1498-1504
29. Bornstein M.B., Miller A., Slagle S., Weitzman M., Crystal H., Drexler E., et al. A Pilot Trial of Cop-1 in Exacerbating Remitting Multiple-Sclerosis. N Engl J Med 317 (1987) 408-414
30. Duda P.W., Schmied M.C., Cook S.L., Krieger J.I., and Hafler D.A. Glatiramer acetate (Copaxone (R)) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis. J Clin Invest 105 (2000) 967-976
31. Neuhaus O., Farina C., Yassouridis A., Wiendl H., Bergh F.T., Dose T., et al. Multiple sclerosis: Comparison of copolymer-1-reactive T cell lines from treated and untreated subjects reveals cytokine shift from T helper 1 to T helper 2 cells. Proc Natl Acad Sci USA 97 (2000) 7452-7457
32. Johnson K.P., Brooks B.R., Cohen J.A., Ford C.C., Goldstein J., Lisak R.P., et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology 45 (1995) 1268-1276
33. Korczyn A.D., and Nisipeanu P. Safety profile of copolymer 1: analysis of cumulative experience in the United States and Israel. J Neurol 243 (1996) S23-S26
34. Weiner H.L., Mackin G.A., Matsui M., Orav E.J., Khoury S.J., Dawson D.M., et al. Double-blind pilot trial of oral tolerization with myelin antigens in multiple sclerosis. Science 259 (1993) 1321-1324
35. Bielekova B., Goodwin B., Richert N., Cortese I., Kondo T., Afshar G., et al. Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand. Nat Med 6 (2000) 1167-1175
36. Kappos L., Comi G., Panitch H., Oger J., Antel J., Conlon P., et al. Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial. The Altered Peptide Ligand in Relapsing MS Study Group. Nat Med 6 (2000) 1176-1182
37. Kennedy M.K., Tan L.J., Dal Canto M.C., Tuohy V.K., Lu Z.J., Trotter J.L., et al. Inhibition of murine relapsing experimental autoimmune encephalomyelitis by immune tolerance to proteolipid protein and its encephalitogenic peptides. J Immunol 144 (1990) 909-915
38. Smith C.E., Eagar T.N., Strominger J.L., and Miller S.D. Differential induction of IgE-mediated anaphylaxis after soluble vs. cell-bound tolerogenic peptide therapy of autoimmune encephalomyelitis. Proc Natl Acad Sci USA 102 (2005) 9595-9600
39. Tan L.J., Kennedy M.K., and Miller S.D. Regulation of the effector stages of experimental autoimmune encephalomyelitis via neuroantigen-specific tolerance induction. II. Fine specificity of effector T cell inhibition. J Immunol 148 (1992) 2748-2755
40. Kennedy M.K., Tan L.J., Dal Canto M.C., and Miller S.D. Regulation of the effector stages of experimental autoimmune encephalomyelitis via neuroantigen-specific tolerance induction. J Immunol 145 (1990) 117-126
41. Tan L.J., Kennedy M.K., Dal Canto M.C., and Miller S.D. Successful treatment of paralytic relapses in adoptive experimental autoimmune encephalomyelitis via neuroantigen- specific tolerance. J Immunol 147 (1991) 1797-1802
42. Peterson J.D., Karpus W.J., Clatch R.J., and Miller S.D. Split tolerance of Th1 and Th2 cells in tolerance to Theiler's murine encephalomyelitis virus. Eur J Immunol 23 (1993) 46-55
43. McRae B.L., Kennedy M.K., Tan L.J., Dal Canto M.C., and Miller S.D. Induction of active and adoptive chronic-relapsing experimental autoimmune encephalomyelitis (EAE) using an encephalitogenic epitope of proteolipid protein. J Neuroimmunol 38 (1992) 229-240
44. +T cells in multiple sclerosis. J Immunol 172 (2004) 3893-3904
45. + T cells. J Immunol 173 (2004) 6526-6531
46. + regulatory T cells. J Exp Med 201 (2005) 1061-1067
47. + regulatory T cells. Int Immunol 16 (2004) 249-256
48. + regulatory cells within the central nervous system. J Immunol 175 (2005) 3025-3032
49. Kennedy M.K., Dal Canto M.C., Trotter J.L., and Miller S.D. Specific immune regulation of chronic-relapsing experimental allergic encephalomyelitis in mice. J Immunol 141 (1988) 2986-2993
50. Chen D.S., Soen Y., Stuge T.B., Lee P.P., Weber J.S., Brown P.O., et al. Marked differences in human melanoma antigen-specific T cell responsiveness after vaccination using a functional microarray. PLOS Med 2 (2005) e265
51. Elliott E.A., McFarland H.I., Nye S.H., Cofiell R., Wilson T.M., Wilkins J.A., et al. Treatment of experimental encephalomyelitis with a novel chimeric fusion protein of myelin basic protein and proteolipid protein. J Clin Invest 98 (1996) 1602-1612
52. Zhong M.C., Kerlero de R.N., and Ben-Nun A. Multiantigen/multiepitope-directed immune-specific suppression of "complex autoimmune encephalomyelitis" by a novel protein product of a synthetic gene. J Clin Invest 110 (2002) 81-90
53. Leadbetter E.A., Bourque C.R., Devaux B., Olson C.D., Sunshine G.H., Hirani S., et al. Experimental autoimmune encephalomyelitis induced with a combination of myelin basic protein and myelin oligodendrocyte glycoprotein is ameliorated by administration of a single myelin basic protein peptide. J Immunol 161 (1998) 504-512
54. Pedotti R., Mitchell D., Wedemeyer J., Karpuj M., Chabas D., Hattab E.M., et al. An unexpected version of horror autotoxicus: anaphylactic shock to a self-peptide. Nat Immunol 2 (2001) 216-222
55. Eagar T.N., Turley D.M., Padilla J., Karandikar N.J., Tan L.J., Bluestone J.A., et al. CTLA-4 regulates expansion and differentiation of Th1 cells following induction of peripheral T cell tolerance. J Immunol 172 (2004) 7442-7450
56. Malotky M.K.H., Pope L., and Miller S.D. Epitope and functional specificity of peripheral tolerance induction in experimental autoimmune encephalomyelitis in adult Lewis rats. J Immunol 153 (1994) 841-851
57. Karpus W.J., Pope J.G., Peterson J.D., Dal Canto M.C., and Miller S.D. Inhibition of Theiler's virus-mediated demyelination by peripheral immune tolerance induction. J Immunol 155 (1995) 947-957
58. + immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J Exp Med 188 (1998) 287-296
59. + naturally anergic and suppressive T cells: induction of autoimmune disease by breaking their anergic/suppressive state. Int Immunol 10 (1998) 1969-1980
60. Piccirillo C.A., Letterio J.J., Thornton A.M., McHugh R.S., Mamura M., Mizuhara H., et al. CD4(+)CD25(+) regulatory T cells can mediate suppressor function in the absence of transforming growth factor beta1 production and responsiveness. J Exp Med 196 (2002) 237-246
61. Dieckmann D., Bruett C.H., Ploettner H., Lutz M.B., and Schuler G. Human CD4(+)CD25(+) regulatory, contact-dependent T cells induce interleukin 10-producing, contact-independent type 1-like regulatory T cells. J Exp Med 196 (2002) 247-253
62. Jonuleit H., Schmitt E., Kakirman H., Stassen M., Knop J., and Enk A.H. Infectious tolerance: human CD25(+) regulatory T cells convey suppressor activity to conventional CD4(+) T helper cells. J Exp Med 196 (2002) 255-260
63. - cells to develop suppressive activity: the role of IL-2, TGF-beta, and IL-10. J Immunol 172 (2004) 5213-5221
64. Bogdan C., and Nathan C. Modulation of macrophage function by transforming growth factor beta, interleukin-4, and interleukin-10. Ann N Y Acad Sci 685 (1993) 713-739
65. Vodovotz Y., and Bogdan C. Control of nitric oxide synthase expression by transforming growth factor-beta: implications for homeostasis. Prog Growth Factor Res 5 (1994) 341-351
66. Tsunawaki S., Sporn M., and Nathan C. Comparison of transforming growth factor-beta and a macrophage- deactivating polypeptide from tumor cells. Differences in antigenicity and mechanism of action. J Immunol 142 (1989) 3462-3468
67. Gorelik L., Constant S., and Flavell R.A. Mechanism of transforming growth factor beta-induced inhibition of T helper type 1 differentiation. J Exp Med 195 (2002) 1499-1505
68. Gorelik L., Fields P.E., and Flavell R.A. Cutting edge: TGF-beta inhibits Th type 2 development through inhibition of GATA-3 expression. J Immunol 165 (2000) 4773-4777
69. Chen C.H., Seguin-Devaux C., Burke N.A., Oriss T.B., Watkins S.C., Clipstone N., et al. Transforming growth factor beta blocks Tec kinase phosphorylation, Ca2+ influx, and NFATc translocation causing inhibition of T cell differentiation. J Exp Med 197 (2003) 1689-1699
70. Capsoni F., Minonzio F., Ongari A.M., Carbonelli V., Galli A., and Zanussi C. IL-10 up-regulates human monocyte phagocytosis in the presence of IL-4 and IFN-gamma. J Leukoc Biol 58 (1995) 351-358
71. Spittler A., Schiller C., Willheim M., Tempfer C., Winkler S., and Boltz-Nitulescu G. IL-10 augments CD23 expression on U937 cells and down-regulates IL-4-driven CD23 expression on cultured human blood monocytes: effects of IL-10 and other cytokines on cell phenotype and phagocytosis. Immunology 85 (1995) 311-317
72. Koppelman B., Neefjes J.J., de Vries J.E., and de Waal Malefyt R. Interleukin-10 down-regulates MHC class II alphabeta peptide complexes at the plasma membrane of monocytes by affecting arrival and recycling. Immunity 7 (1997) 861-871
73. Willems F., Marchant A., Delville J.P., Gerard C., Delvaux A., Velu T., et al. Interleukin-10 inhibits B7 and intercellular adhesion molecule-1 expression on human monocytes. Eur J Immunol 24 (1994) 1007-1009
74. + regulatory T cells control autoimmunity?. Curr Opin Immunol 17 (2005) 638-642